RBCC: 2012 could turn out to be better for the global biotechnology sector

With strong growth predicted for the biotech and pharmaceuticals industry in 2012, emerging biotech firm Rainbow Coral Corp. (OTCBB:RBCC) anticipates a prosperous new year ahead.

“The biotech industry delivered solid top-to-bottom growth this year, producing record-breaking profits”

Industry researcher RNCOS predicts that the global pharma industry will grow at a CAGR of 6.5 percent over the next two years. Many analysts say that increasing affordability, increasing disease prevalence, and rising healthcare spending will drive growth in the pharmaceutical market in 2012.

Biotechnology, in particular, is expected to shine. The biotech market enjoyed a prosperous year in 2011, a trend expected by many experts to continue into 2012.

"The biotech industry delivered solid top-to-bottom growth this year, producing record-breaking profits," said RBCC CEO Patrick Brown. "2012 could turn out to be even better. This is the perfect time for a growth-oriented company like RBCC to break into the global biotechnology sector."

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Celgene Corp. (NASDAQ: CELG), Cardinal Health, Inc. (NYSE: CAH), Abbott Laboratories (NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY).

Source Rainbow BioSciences